Top Markets
Coin of the day
Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc.

6838
주식 순위 #20880
Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei... Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei City, Taiwan, is actively engaged in both late-preclinical and early clinical development stages. Its core focus lies in pioneering therapeutic candidates across ophthalmology, oncology, and anti-infective domains. Among its key investigational assets is APP13007, an ophthalmic nanosuspension, currently progressing through Phase III trials for managing post-surgical discomfort and inflammation of the eye. The company's portfolio also encompasses TSY-0110, designed as an antibody-drug conjugate, and TSY-0210, an antibiotic targeting resilient drug-resistant infections. Further compounds under development include APP13002, a topical antibiotic intended for ocular infections like blepharitis, and MPT0E028, a novel pan-histone deacetylase inhibitor being explored for solid malignancies such as hepatomas and colorectal cancer, in addition to lung fibrosis. Additionally, Formosa Pharmaceuticals maintains a collaborative partnership with Eyenovia, Inc., dedicated to advancing innovative ophthalmic treatments. Established in 2010, the company is headquartered in Taiwan's capital.
주가
$0.79338575
마지막 동기화: 2026-07-28
시가총액
$119.78M
변동 (1일)
2.67%
변동 (1년)
-27.61%
국가
TW
거래 Formosa Pharmaceuticals, Inc. (6838)

카테고리

Formosa Pharmaceuticals, Inc. (6838)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Formosa Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Formosa Pharmaceuticals, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH